首页 中华传染病杂志 2024年42卷09期 艾滋病合并侵袭性真菌病诊治专家共识(更新版)
中华传染病杂志
期刊首页
过刊列表
高级检索
稿件发表
• 共识与指南 •
ENGLISH ABSTRACT
艾滋病合并侵袭性真菌病诊治专家共识(更新版)
国家感染性疾病临床医学研究中心
欧美同学会·中国留学人员联谊会医师协会传染病分会
广东省医学会微生态医学分会
作者及单位信息
·
DOI： 10.3760/cma.j.cn311365-20240621-00182
Chinese guideline on the diagnosis and treatment of invasive fungal diseases in people living with human immunodeficiency virus/acquired immune deficiency syndrome (edition update)
National Clinical Research Center for Infectious Diseases
The Infectious Diseases Branch of the Medical Association of Western Returned Scholars Association (Overseas-educated Scholars Association of China)
The Microecology Medicine Branch of Guangdong Medical Association
Lu Hongzhou
Li Taisheng
Shen Yinzhong
Authors Info & Affiliations
National Clinical Research Center for Infectious Diseases
The Infectious Diseases Branch of the Medical Association of Western Returned Scholars Association (Overseas-educated Scholars Association of China)
The Microecology Medicine Branch of Guangdong Medical Association
Lu Hongzhou
National Clinical Research Center for Infectious Diseases, Department of Infection and Immunity, Shenzhen Third People′s Hospital, Shenzhen 518112, China
Li Taisheng
Department of Infectious Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Peking Union Medical College Hospital, Beijing 100730, China
Shen Yinzhong
Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
·
DOI： 10.3760/cma.j.cn311365-20240621-00182
279
102
0
0
2
0
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
侵袭性真菌病(IFD)是艾滋病患者常见的机会性感染，也是患者住院和死亡的常见原因。艾滋病合并IFD患者的诊治相对于一般人群而言更为复杂和困难。近2年来，国内外相继发布与更新了多部IFD诊断和治疗的指南与共识。本共识由国家感染性疾病临床医学研究中心和欧美同学会·中国留学人员联谊会医师协会传染病分会牵头，组织相关学会共同修改与更新。在参照国内外指南撰写规范和2019版《艾滋病合并侵袭性真菌病诊治专家共识》的基础上，不仅对艾滋病人群中常见IFD的诊断和治疗进行更新，而且增加了新发IFD的诊治，最终形成艾滋病患者IFD的诊疗推荐意见，包括了制订的方法和流程、侵袭性念珠菌病、马尔尼菲篮状菌病、侵袭性曲霉病、隐球菌病、肺孢子菌肺炎、新发IFD的诊治等七部分内容，将为推进艾滋病人群的IFD诊治发挥积极作用。
HIV/AIDS;侵袭性真菌病;共识;诊治;更新
引用本文
国家感染性疾病临床医学研究中心,欧美同学会·中国留学人员联谊会医师协会传染病分会,广东省医学会微生态医学分会. 艾滋病合并侵袭性真菌病诊治专家共识(更新版)[J]. 中华传染病杂志,2024,42(09)：513-529.
DOI:10.3760/cma.j.cn311365-20240621-00182PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
0分
[累计0个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
HIV感染仍是全球重要的公共卫生问题
[
1
]。侵袭性真菌病(invasive fungal diseases，IFD)是HIV感染者进入AIDS期的重要的常见机会性感染，其特有的流行病学特点和疾病谱是导致AIDS患者死亡的原因之一
[
2
,
3
,
4
]。AIDS患者存在明显的免疫缺陷，所以合并IFD病例的诊治思维和策略均有自身特点，其诊治相对于一般人群而言也更为复杂和困难。近2年来国内外IFD相关诊治均取得了显著进展，并相继发布和更新了相关的指南和共识。为了更新与进一步规范AIDS合并IFD的诊治，由国家感染性疾病临床医学研究中心和欧美同学会·中国留学人员联谊会医师协会传染病分会牵头，组织相关学会共同编写了本共识。在2019版《艾滋病合并侵袭性真菌病诊治专家共识》
[
5
]的基础上，参考国内外其他真菌感染相关指南中的相关内容，遵循系统评价与证据质量进行修订，主要突出HIV/AIDS患者合并常见IFD的诊断和治疗更新部分，同时增加了新发IFD的诊治内容。
参考文献
[1]
WHO. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022-2030: report on progress and gaps 2024, second edition[M/OL]. Geneva:World Health Organization, 2024(2024-05-22)[2024-06-21]. https://www.who.int/publications/i/item/9789240094925.
[2]
Limper AH , Adenis A , Le T ,et al. Fungal infections in HIV/AIDS[J]. Lancet Infect Dis, 2017，17(11)：e334-e343. DOI:
10.1016/S1473-3099(17)30303-1
.
[3]
Denning DW . Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized[J]. Philos Trans R Soc Lond B Biol Sci, 2016，371(1709)：20150468. DOI:
10.1098/rstb.2015.0468
.
[4]
Ji Y , Wang Z , Shen J ,et al. Trends and characteristics of all-cause mortality among HIV-infected inpatients during the HAART era (2006-2015) in Shanghai, China[J]. Biosci Trends, 2017，11(1)：62-68. DOI:
10.5582/bst.2016.01195
.
[5]
中华医学会热带病与寄生虫学分会艾滋病学组. 艾滋病合并侵袭性真菌病诊治专家共识[J]. 中华传染病杂志， 2019，37(10)：581-593. DOI:
10.3760/cma.j.issn.1000-6680.2019.10.002
.
[6]
Pfaller MA , Diekema DJ , Turnidge JD ,et al.
Twenty years of the SENTRY antifungal surveillance program: results for
Candida
species from 1997-2016
[J]. Open Forum Infect Dis, 2019，6(Suppl 1)：S79-S94. DOI:
10.1093/ofid/ofy358
.
[7]
Kullberg BJ , Arendrup MC . Invasive candidiasis[J]. N Engl J Med, 2015,373(15)：1445-1456. DOI:
10.1056/NEJMra1315399
.
[8]
Barantsevich N , Barantsevich E . Diagnosis and treatment of invasive candidiasis[J]. Antibiotics (Basel), 2022，11(6)：718. DOI:
10.3390/antibiotics11060718
.
[9]
Sakai D , Matsumiya W , Kusuhara S ,et al. Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia[J]. J Ophthalmic Inflamm Infect, 2021，11(1)：17. DOI:
10.1186/s12348-021-00248-0
.
[10]
Brooks RG .
Prospective study of
Candida
endophthalmitis in hospitalized patients with candidemia
[J]. Arch Intern Med, 1989，149(10)：2226-2228. DOI：
10.1001/archinte.1989.00390100056014
.
[11]
Lu Y , Chen YQ , Guo YL ,et al. Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: a bivariate meta-analysis[J]. Intern Med， 2011，50(22)：2783-2791. DOI:
10.2169/internalmedicine.50.6175
.
[12]
Murri R , Camici M , Posteraro B ,et al. Performance evaluation of the (1，3)-β-D-glucan detection assay in non-intensive care unit adult patients[J]. Infect Drug Resist, 2019，12：19-24. DOI:
10.2147/IDR.S181489
.
[13]
Jaijakul S , Vazquez JA , Swanson RN ,et al. (1，3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis[J]. Clin Infect Dis, 2012,55(4)：521-526. DOI:
10.1093/cid/cis456
.
[14]
Walsh TJ , Katragkou A , Chen T ,et al. Invasive candidiasis in infants and children: recent advances in epidemiology, diagnosis, and treatment[J]. J Fungi (Basel), 2019,5(1)：11. DOI:
10.3390/jof5010011
.
[15]
Patterson TF , Donnelly JP . New concepts in diagnostics for invasive mycoses: non-culture-based methodologies[J]. J Fungi (Basel), 2019,5(1)：9. DOI:
10.3390/jof5010009
.
[16]
Barnes RA , White PL , Morton CO ,et al. Diagnosis of aspergillosis by PCR: clinical considerations and technical tips[J]. Med Mycol, 2018，56(suppl_1)：60-72. DOI:
10.1093/mmy/myx091
.
[17]
Zacharioudakis IM , Zervou FN , Mylonakis E . T2 magnetic resonance assay: overview of available data and clinical implications[J]. J Fungi (Basel)， 2018，4(2)：45. DOI:
10.3390/jof4020045
.
[18]
Scherer E , Iriart X , Bellanger AP ,et al. Quantitative PCR (qPCR) detection of mucorales DNA in bronchoalveolar lavage fluid to diagnose pulmonary mucormycosis[J]. J Clin Microbiol, 2018,56(8)：e00289-00218. DOI:
10.1128/JCM.00289-18
.
[19]
Hammarström H , StjärneAspelund A , Christensson B ,et al. Prospective evaluation of a combination of fungal biomarkers for the diagnosis of invasive fungal disease in high-risk haematology patients[J]. Mycoses, 2018，61(9)：623-632. DOI:
10.1111/myc.12773
.
[20]
Boch T , Spiess B , Cornely OA ,et al.
Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1，3-β-D-glucan,
Aspergillus
PCR, multifungal DNA-microarray, and
Aspergillus
azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study
[J]. Clin Microbiol Infect, 2016,22(10)：862-868. DOI:
10.1016/j.cmi.2016.06.021
.
[21]
中国成人念珠菌病诊断与治疗专家共识组. 中国成人念珠菌病诊断与治疗专家共识[J]. 中华传染病杂志， 2020,38(1)：29-43. DOI:
10.3760/cma.j.issn.1000-6680.2020.01.005
.
[22]
Rafat Z , Sasani E , Salimi Y ,et al. The prevalence, etiological agents, clinical features, treatment, and diagnosis of HIV-associated oral candidiasis in pediatrics across the world: a systematic review and meta-analysis[J]. Front Pediatr， 2021，9：805527. DOI:
10.3389/fped.2021.805527
.
[23]
Clancy CJ , Nguyen MH .
Finding the
"
missing 50%
"
of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care
[J]. Clin Infect Dis, 2013,56(9)：1284-1292. DOI:
10.1093/cid/cit006
.
[24]
Morrell M , Fraser VJ , Kollef MH .
Delaying the empiric treatment of
Candida
bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality
[J]. Antimicrob Agents Chemother, 2005，49(9)：3640-3645. DOI:
10.1128/AAC.49.9.3640-3645.2005
.
[25]
Agnelli C , Valerio M , Bouza E ,et al. Persistent candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era[J]. Eur J Clin Microbiol Infect Dis, 2019，38(3)：607-614. DOI:
10.1007/s10096-019-03477-3
.
[26]
Andes DR , Safdar N , Baddley JW ,et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials[J]. Clin Infect Dis, 2012，54(8)：1110-1122. DOI:
10.1093/cid/cis021
.
[27]
Vazquez J , Reboli AC , Pappas PG ,et al. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial[J]. BMC Infect Dis, 2014，14(1):97. DOI:
10.1186/1471-2334-14-97
.
[28]
Jaffal K , Poissy J , Rouze A ,et al.
De-escalation of antifungal treatment in critica
lly ill patients with suspected invasive
Candida
infection: incidence, associated factors, and safety
[J]. Ann Intensive Care, 2018，8(1)：49. DOI:
10.1186/s13613-018-0392-8
.
[29]
Garnacho-Montero J , Díaz-Martín A , García-Cabrera E ,et al.
Impact on hospital mortality of catheter removal and adequate antifungal therapy in
Candida
spp. bloodstream infections
[J]. J Antimicrob Chemother， 2013，68(1)：206-213. DOI:
10.1093/jac/dks347
.
[30]
Guarana M , Nucci M . Acute disseminated candidiasis with skin lesions: a systematic review[J]. Clin Microbiol Infect, 2018，24(3)：246-250. DOI:
10.1016/j.cmi.2017.08.016
.
[31]
De Castro N , Mazoyer E , Porcher R ,et al. Hepatosplenic candidiasis in the era of new antifungal drugs: a study in Paris 2000-2007[J]. Clin Microbiol Infect, 2012，18(6)：E185-187. DOI:
10.1111/j.1469-0691.2012.03819.x
.
[32]
Le T , Wolbers M , Chi NH ,et al.
Epidemiology, seasonality, and predictors of outcome of AIDS-associated
Penicillium marneffei
infection in Ho Chi Minh City, Viet Nam
[J]. Clin Infect Dis, 2011,52(7)：945-952. DOI:
10.1093/cid/cir028
.
[33]
Larsson M , Nguyen LH , Wertheim HF ,et al.
Clinical characteristics and outcome of
Penicillium marneffei
infection among HIV-infected patients in northern Vietnam
[J]. AIDS Res Ther, 2012,9(1)：24. DOI:
10.1186/1742-6405-9-24
.
[34]
Jiang J , Meng S , Huang S ,et al.
Effects of
Talaromyces marneffei
infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study
[J]. Clin Microbiol Infect, 2019，25(2)：233-241. DOI:
10.1016/j.cmi.2018.04.018
.
[35]
Luo B , Sun J , Cai R ,et al. Spectrum of opportunistic infections and risk factors for in-hospital mortality of admitted AIDS patients in Shanghai[J]. Medicine (Baltimore), 2016，95(21)：e3802. DOI:
10.1097/MD.0000000000003802
.
[36]
杨振铭，黄捷，陈香梅，等. 马尔尼菲篮状菌病合并其他机会性感染的临床特征研究进展[J]. 中华结核和呼吸杂志， 2023,46(5)：503-506. DOI:
10.3760/cma.j.cn112147-20220807-00659
.
[37]
Zheng J , Gui X , Cao Q ,et al.
A clinical study of acquired immunodeficiency syndrome associated
Penicillium marneffei
infection from a non-endemic area in China
[J]. PLoS One, 2015，10(6)：e0130376. DOI:
10.1371/journal.pone.0130376
.
[38]
何小庆，鲁雁秋，周怡宏，等. 重庆地区56例AIDS合并播散性马尔尼菲篮状菌病患者临床特征及死亡危险因素分析[J]. 传染病信息， 2018,31(6)：521-524. DOI:
10.3969/j.issn.1007-8134.2018.06.006
.
[39]
Qin Y , Huang X , Chen H ,et al.
Burden of
Talaromyces marneffei
infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis
[J]. BMC Infect Dis， 2020，20(1)：551. DOI:
10.1186/s12879-020-05260-8
.
[40]
Chen J , Zhang R , Shen Y ,et al. Clinical characteristics and prognosis of penicilliosis among human immunodeficiency virus-infected patients in Eastern China[J]. Am J Trop Med Hyg, 2017,96(6)：1350-1354. DOI:
10.4269/ajtmh.16-0521
.
[41]
中华医学会感染病学分会艾滋病丙型肝炎学组，陈耀凯，李太生，等. 艾滋病合并马尔尼菲篮状菌病诊疗专家共识(2024年更新版)[J]. 中国艾滋病性病， 2024，30(6)：563-572. DOI:
10.13419/j.cnki.aids.2024.06.02
.
[42]
Vanittanakom N , Cooper CR, Jr,
<x>Fis</x>
<x>her</x>
MC ,et al.
Penicillium marneffei
infection and recent advances in the epidemiology and molecular biology aspects
[J]. Clin Microbiol Rev, 2006，19(1)：95-110. DOI:
10.1128/CMR.19.1.95-110.2006
.
[43]
Ranjana KH , Priyokumar K , Singh TJ ,et al.
Disseminated
Penicillium marneffei
infection among HIV-infected patients in Manipur state, India
[J]. J Infect, 2002，45(4)：268-271. DOI:
10.1053/jinf.2002.1062
.
[44]
李勇，蒙志好，苏凌松，等. 艾滋病合并马尔尼菲青霉病256例临床研究[J]. 中国真菌学杂志， 2009，4(6)：347-350. DOI:
10.3969/j.issn.1673-3827.2009.06.007
.
[45]
Khieu C , Apivatthakakul A , Kunavisarut P ,et al.
Case report: bilateral granulomatous anterior uveitis in HIV-patient with disseminated
Talaromycosis
(
Penicilliosis
)
marneffei
infection
[J]. Ocul Immunol Inflamm, 2020，28(7)：1066-1068. DOI:
10.1080/09273948.2019.1657468
.
[46]
Vilar FJ , Hunt R , Wilkins EG ,et al.
Disseminated
Penicillium marneffei
in a patient infected with human immunodeficiency virus
[J]. Int J STD AIDS， 2000，11(2)：126-128. DOI:
10.1177/095646240001100212
.
[47]
Supparatpinyo K , Khamwan C , Baosoung V ,et al.
Disseminated
Penicillium marneffei
infection in southeast Asia
[J]. Lancet, 1994，344(8915)：110-113. DOI:
10.1016/s0140-6736(94)91287-4
.
[48]
Thu N , Chan J , Ly VT ,et al. Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of talaromycosis[J]. Clin Infect Dis, 2021，73(2)：e330-e336. DOI:
10.1093/cid/ciaa826
.
[49]
屠大朋，熊倩妤，杨兴林，等. G试验联合PCT、IL-6对艾滋病合并马尔尼菲篮状菌病的诊断价值[J]. 中外医学研究， 2023，21(20)：75-78. DOI:
10.14033/j.cnki.cfmr.2023.20.019
.
[50]
Li X , Zheng Y , Wu F ,et al.
Evaluation of quantitative real-time PCR and Platelia galactomannan assays for the diagnosis of disseminated
Talaromyces marneffei
infection
[J]. Med Mycol, 2020,58(2)：181-186. DOI:
10.1093/mmy/myz052
.
[51]
Narayanasamy S , Dat VQ , Thanh NT ,et al.
A global call for talaromycosis to be recogni
sed as a neglected tropical disease
[J]. Lancet Glob Health, 2021,9(11)：e1618-e1622. DOI:
10.1016/S2214-109X(21)00350-8
.
[52]
Chen X , Ou X , Wang H ,et al.
Talaromyces marneffei
Mp1p antigen detection may play an important role in the early diagnosis of talaromycosis in patients with acquired immunodeficiency syndrome
[J]. Mycopathologia, 2022，187(2/3)：205-215. DOI:
10.1007/s11046-022-00618-9
.
[53]
Ning C , Lai J , Wei W ,et al.
Accuracy of rapid diagnosis of
Talaromyces marneffei:
a systematic review and meta-analysis
[J]. PLoS One, 2018，13(4)：e0195569. DOI:
10.1371/journal.pone.0195569
.
[54]
Liu L , Sun B , Ying W ,et al.
Rapid diagnosis of
Talaromyces marneffei
infection by metagenomic next-generation sequencing technology in a Chinese cohort of inborn errors of immunity
[J]. Front Cell Infect Microbiol, 2022，12：987692. DOI:
10.3389/fcimb.2022.987692
.
[55]
Zaongo SD , Zhang F , Chen Y . An overview of diagnostic and management strategies for talaromycosis, an underrated disease[J]. J Fungi (Basel), 2023，9(6)：647. DOI:
10.3390/jof9060647
.
[56]
Ouyang Y , Cai S , Liang H ,et al.
Administration of voriconazole in disseminated
Talaromyces
(
Penicillium
)
marneffei
infection: a retrospective study
[J]. Mycopathologia, 2017，182(5/6)：569-575. DOI:
10.1007/s11046-016-0107-3
.
[57]
Supparatpinyo K , Schlamm HT .
Voriconazole as therapy for systemic
Penicillium marneffei
infections in AIDS patients
[J]. Am J Trop Med Hyg, 2007，77(2)：350-353. DOI：
10.4269/AJTMH.2007.77.350
.
[58]
Qin Y , Zhou Y , Liu S ,et al. HIV-associated talaromycosis: does timing of antiretroviral therapy matter？[J]. J Infect, 2022，84(3)：410-417. DOI:
10.1016/j.jinf.2021.12.032
.
[59]
Tong KB , Lau CJ , Murtagh K ,et al. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups[J]. Int J Infect Dis, 2009，13(1)：24-36. DOI:
10.1016/j.ijid.2008.02.013
.
[60]
Denning DW , Morgan EF .
Quantifying deaths from aspergillosis in H
IV positive people
[J]. J Fungi (Basel)， 2022，8(11)：1131. DOI:
10.3390/jof8111131
.
[61]
Singh RK . Chronic pulmonary aspergillosis in a patient with AIDS[J]. Cureus, 2021,13(4)：e14588. DOI:
10.7759/cureus.14588
.
[62]
Mylonakis E , Barlam TF , Flanigan T ,et al. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases[J]. Chest, 1998，114(1)：251-262. DOI:
10.1378/chest.114.1.251
.
[63]
Cordonnier C , Maury S , Pautas C ,et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients[J]. Bone Marrow Transplant, 2004，33(9)：943-948. DOI:
10.1038/sj.bmt.1704469
.
[64]
Minamoto GY , Rosenberg AS . Fungal infections in patients with acquired immunodeficiency syndrome[J]. Med Clin North Am, 1997,81(2)：381-409. DOI:
10.1016/s0025-7125(05)70523-x
.
[65]
Denis B , Guiguet M , de Castro N ,et al. Relevance of EORTC criteria for the diagnosis of invasive aspergillosis in HIV-infected patients, and survival trends over a 20-year period in France[J]. Clin Infect Dis， 2015，61(8)：1273-1280. DOI:
10.1093/cid/civ492
.
[66]
Thompson GR 3rd , Patterson TF . Pulmonary aspergillosis[J]. Semin Respir Crit Care Med， 2008，29(2)：103-110. DOI:
10.1055/s-2008-1063849
.
[67]
De Pauw B , Walsh TJ , Donnelly JP ,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group[J]. Clin Infect Dis, 2008,46(12)：1813-1821. DOI:
10.1086/588660
.
[68]
Donnelly JP , Chen SC , Kauffman CA ,et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium[J]. Clin Infect Dis， 2020，71(6)：1367-1376. DOI:
10.1093/cid/ciz1008
.
[69]
Arvanitis M , Ziakas PD , Zacharioudakis IM ,et al. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance[J]. J Clin Microbiol, 2014，52(10)：3731-3742. DOI:
10.1128/JCM.01365-14
.
[70]
Cruciani M , Mengoli C , Loeffler J ,et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people[J]. Cochrane Database Syst Rev, 2015(10)：CD009551. DOI:
10.1002/14651858.CD009551.pub3
.
[71]
White PL , Bretagne S , Caliendo AM ,et al. Aspergillus polymerase chain reaction：an update on technical recommendations, clinical applications, and justification for inclusion in the second revision of the EORTC/MSGERC definitions of invasive fungal disease[J]. Clin Infect Dis, 2021，72(Suppl 2)：S95-S101. DOI:
10.1093/cid/ciaa1865
.
[72]
Steinbach WJ , Benjamin DK, Jr, Kontoyiannis DP ,et al.
Infections due to
Aspergillus terreus:
a multicenter retrospective analysis of 83 cases
[J]. Clin Infect Dis, 2004，39(2)：192-198. DOI:
10.1086/421950
.
[73]
Chen K , Zhang X , Ke X ,et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society[J]. Ther Drug Monit, 2018,40(6)：663-674. DOI:
10.1097/FTD.0000000000000561
.
[74]
陈恳，张相林，克晓燕，等. 《伏立康唑个体化用药指南》解读[J]. 临床药物治疗杂志， 2019，17(3)：47-52，78. DOI:
10.3969/j.issn.1672-3384.2019.03.012
.
[75]
Ullmann AJ , Aguado JM , Arikan-Akdagli S ,et al.
Diagnosis and management of
Aspergillus
diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
[J]. Clin Microbiol Infect, 2018，24：Suppl 1-e1. e38DOI:
10.1016/j.cmi.2018.01.002
.
[76]
Aliff TB , Maslak PG , Jurcic JG ,et al.
Refractory
Aspergillus
pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin
[J]. Cancer, 2003,97(4)：1025-1032. DOI:
10.1002/cncr.11115
.
[77]
Kontoyiannis DP , Hachem R , Lewis RE ,et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies[J]. Cancer, 2003，98(2)：292-299. DOI:
10.1002/cncr.11479
.
[78]
Marr KA , Boeckh M , Carter RA ,et al. Combination antifungal therapy for invasive aspergillosis[J]. Clin Infect Dis， 2004，39(6)：797-802. DOI:
10.1086/423380
.
[79]
Gonçalves SS , Souza A , Chowdhary A ,et al.
Epidemiology and molecular mechanisms of antifungal resistance in
Candida
and
Aspergillus
[J]. Mycoses, 2016,59(4)：198-219. DOI:
10.1111/myc.12469
.
[80]
Buil JB , Snelders E , Denardi LB ,et al.
Trends in azole resistance in
Aspergillus fumigatus,
the Netherlands, 1994-2016
[J]. Emerg Infect Dis, 2019,25(1)：176-178. DOI:
10.3201/eid2501.171925
.
[81]
Pham CD , Reiss E , Hagen F ,et al.
Passive surveillance for azole-resistant
Aspergillus fumigatus,
United States, 2011-2013
[J]. Emerg Infect Dis, 2014，20(9)：1498-1503. DOI:
10.3201/eid2009.140142
.
[82]
Liu M , Zeng R , Zhang L ,et al.
Multiple cyp51A-based mechanisms identified in azole-resistant isolates of
Aspergillus fumigatus
from China
[J]. Antimicrob Agents Chemother, 2015，59(7)：4321-4325. DOI:
10.1128/AAC.00003-15
.
[83]
Chen Y , Lu Z , Zhao J ,et al.
Epidemiology and molecular characterizations of azole resistance in clinical and environmental
Aspergillus fumigatus
isolates from China
[J]. Antimicrob Agents Chemother, 2016，60(10)：5878-5884. DOI:
10.1128/AAC.01005-16
.
[84]
Morrissey CO , Chen SC , Sorrell TC ,et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial[J]. Lancet Infect Dis, 2013，13(6)：519-528. DOI:
10.1016/S1473-3099(13)70076-8
.
[85]
Hebart H , Klingspor L , Klingebiel T ,et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT[J]. Bone Marrow Transplant, 2009,43(7)：553-561. DOI:
10.1038/bmt.2008.355
.
[86]
Patterson TF , Thompson GR 3rd , Denning DW ,et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016,63(4)：e1-e60. DOI:
10.1093/cid/ciw326
.
[87]
Baron O , Guillaumé B , Moreau P ,et al. Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases[J]. J Thorac Cardiovasc Surg, 1998，115(1)：63-68;
10.1016/s0022-5223(98)70443-x
. DOI:.
[88]
Hasse B , Strebel B , Thurnheer R ,et al. Chronic necrotizing pulmonary aspergillosis after tuberculosis in an HIV-positive woman: an unusual immune reconstitution phenomenon？[J]. AIDS， 2005，19(18)：2179-2181. DOI:
10.1097/01.aids.0000194796.20928.f0
.
[89]
Sambatakou H , Denning DW . Invasive pulmonary aspergillosis transformed into fatal mucous impaction by immune reconstitution in an AIDS patient[J]. Eur J Clin Microbiol Infect Dis， 2005，24(9)：628-633. DOI:
10.1007/s10096-005-0006-x
.
[90]
Rajasingham R , Smith RM , Park BJ ,et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis[J]. Lancet Infect Dis, 2017,17(8)：873-881. DOI:
10.1016/S1473-3099(17)30243-8
.
[91]
Zhao Y , Ye L , Zhao F ,et al.
Cryptococcus neoformans,
a global threat to human health
[J]. Infect Dis Poverty, 2023，12(1)：20. DOI:
10.1186/s40249-023-01073-4
.
[92]
Williamson PR , Jarvis JN , Panackal AA ,et al. Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy[J]. Nat Rev Neurol, 2017，13(1)：13-24. DOI:
10.1038/nrneurol.2016.167
.
[93]
Fisher KM , Montrief T , Ramzy M ,et al. Cryptococcal meningitis: a review for emergency clinicians[J]. Intern Emerg Med, 2021，16(4)：1031-1042. DOI:
10.1007/s11739-020-02619-2
.
[94]
Hsiao PJ , Cheng H , Kao YH ,et al. Comparison of laboratory diagnosis, clinical manifestation, and management of pulmonary cryptococcosis: report of the clinical scenario and literature review[J]. Clin Chim Acta, 2022,524：78-83. DOI:
10.1016/j.cca.2021.11.017
.
[95]
Abassi M , Boulware DR , Rhein J . Cryptococcal meningitis: diagnosis and management update[J]. Curr Trop Med Rep, 2015,2(2)：90-99. DOI:
10.1007/s40475-015-0046-y
.
[96]
中华医学会感染病学分会. 隐球菌性脑膜炎诊治专家共识[J]. 中华传染病杂志， 2018,36(4)：193-199. DOI：
10.3760/cma.j.issn.1000-6680.2018.04.001
.
[97]
Perfect JR , Bicanic T . Cryptococcosis diagnosis and treatment: what do we know now[J]. Fungal Genet Biol, 2015，78：49-54. DOI:
10.1016/j.fgb.2014.10.003
.
[98]
Zhao H , Zhou M , Zheng Q ,et al. Clinical features and outcomes of cryptococcemia patients with and without HIV infection[J]. Mycoses, 2021,64(6)：656-667. DOI:
10.1111/myc.13261
.
[99]
Xu L , Tao R , Wu J ,et al. Short-course rather than low-dose amphotericin B may exert potential influence on mortality in cryptococcal meningitis patients treated with amphotericin B plus flucytosine alone or in combination with fluconazole[J]. Front Microbiol, 2019,10：2082. DOI:
10.3389/fmicb.2019.02082
.
[100]
Chou R , Gordon DB , de Leon-Casasola OA ,et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists′ Committee on Regional Anesthesia, Executive Committee, and Administrative Council[J]. J Pain, 2016，17(2)：131-157. DOI:
10.1016/j.jpain.2015.12.008
.
[101]
Jarvis JN , Lawrence DS , Meya DB ,et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis[J]. N Engl J Med, 2022，386(12)：1109-1120. DOI:
10.1056/NEJMoa2111904
.
[102]
Nussbaum JC , Jackson A , Namarika D ,et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi[J]. Clin Infect Dis, 2010,50(3)：338-344. DOI:
10.1086/649861
.
[103]
Molloy SF , Kanyama C , Heyderman RS ,et al. Antifungal combinations for treatment of cryptococcal meningitis in Africa[J]. N Engl J Med, 2018，378(11)：1004-1017. DOI:
10.1056/NEJMoa1710922
.
[104]
Zhao T , Xu X , Wu Y ,et al. Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China[J]. BMC Infect Dis, 2022，22(1)：677. DOI:
10.1186/s12879-022-07665-z
.
[105]
Zhao H , Lu Y , Li S ,et al. Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment[J]. Mycoses, 2024,67(1)：e13674. DOI:
10.1111/myc.13674
.
[106]
Perfect JR , Dismukes WE , Dromer F ,et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2010,50(3)：291-322. DOI:
10.1086/649858
.
[107]
Powderly WG , Saag MS , Cloud GA ,et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group[J]. N Engl J Med， 1992，326(12)：793-798. DOI:
10.1056/NEJM199203193261203
.
[108]
Rajasingham R , Wake RM , Beyene T ,et al. Cryptococcal meningitis diagnostics and screening in the era of point-of-care laboratory testing[J]. J Clin Microbiol, 2019，57(1)：e01238-01218. DOI:
10.1128/JCM.01238-18
.
[109]
Graybill JR , Sobel J , Saag M ,et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups[J]. Clin Infect Dis, 2000,30(1)：47-54. DOI:
10.1086/313603
.
[110]
Hu Z , Yang Y , Cheng J ,et al. The use of mannitol in HIV-infected patients with symptomatic cryptococcal meningitis[J]. Drug Discov Ther, 2017，10(6)：329-333. DOI:
10.5582/ddt.2016.01054
.
[111]
Rolfes MA , Hullsiek KH , Rhein J ,et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis[J]. Clin Infect Dis, 2014,59(11)：1607-1614. DOI:
10.1093/cid/ciu596
.
[112]
Xu XL , Zhao T , Huang YQ ,et al. Therapeutic lumbar puncture and lumbar drainage: which is more effective for the management of intracranial hypertension in HIV patients with cryptococcal meningitis? Results of a prospective non-randomized interventional study in China[J]. Curr Med Res Opin, 2022,38(5)：803-810. DOI:
10.1080/03007995.2022.2047539
.
[113]
Tao R , Peng X , Liu X ,et al.
Outco
me of lenalidomide treatment for cognitive impairment caused by immune reconstitution inflammatory syndrome in patients with HIV-related cryptococcal meningitis
[J]. J Inflamm Res, 2022，15：5327-5336. DOI:
10.2147/JIR.S374333
.
[114]
钮正春，施学忠. 123例艾滋病合并肺孢子菌肺炎的临床特点分析[J]. 河南医学研究， 2010,19(3)：304-307. DOI:
10.3969/j.issn.1004-437x2010.03.016
.
[115]
马孝煜，王敏，刘纯. 艾滋病合并肺孢子菌肺炎23例临床分析[J]. 中国感染控制杂志， 2015(7)：459-463. DOI:
10.3969/j.issn.1671-9638.2015.07.007
.
[116]
李凌华，唐小平，邓西龙，等. 艾滋病合并肺孢子菌肺炎69例临床分析[J]. 中华传染病杂志， 2008，26(12)：739-743. DOI:
10.3321/j.issn:1000-6680.2008.12.008
.
[117]
Cilloniz C , Torres A , Polverino E ,et al. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome[J]. Eur Respir J, 2014，43(6)：1698-1708. DOI:
10.1183/09031936.00155813
.
[118]
Cillóniz C , Dominedò C , Álvarez-Martínez MJ ,et al.
Pneumocystis
pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
[J]. Expert Rev Anti Infect Ther， 2019，17(10)：787-801. DOI:
10.1080/14787210.2019.1671823
.
[119]
Liu Y , Su L , Jiang SJ ,et al.
Risk factors for mortality from
Pneumocystis carinii
pneumonia (PCP) in non-HIV patients: a meta-analysis
[J]. Oncotarget, 2017，8(35)：59729-59739. DOI:
10.18632/oncotarget.19927
.
[120]
Roux A , Canet E , Valade S ,et al.
Pneumocystis jirovecii
pneumonia in patients with or without AIDS, France
[J]. Emerg Infect Dis, 2014，20(9)：1490-1497. DOI:
10.3201/eid2009.131668
.
[121]
Selwyn PA , Pumerantz AS , Durante A ,et al.
Clinical predictors of
Pneumocystis carinii
pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients
[J]. AIDS, 1998，12(8)：885-893. DOI:
10.1097/00002030-199808000-00011
.
[122]
Kim JH , Psevdos G, Jr, Gonzalez E ,et al. All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART)[J]. Infection, 2013,41(2)：545-551. DOI:
10.1007/s15010-012-0386-7
.
[123]
Hidalgo A , Falcó V , Mauleón S ,et al.
Accuracy of high-resolution CT in distinguishing between
Pneumocystis carinii
pneumonia and non-
Pneumocystis carinii
pneumonia in AIDS patients
[J]. Eur Radiol, 2003，13(5)：1179-1184. DOI:
10.1007/s00330-002-1641-6
.
[124]
Cruciani M , Marcati P , Malena M ,et al.
Meta-analysis of diagnostic procedures for
Pneumocystis carinii
pneumonia in HIV-1-infected patients
[J]. Eur Respir J, 2002，20(4)：982-989. DOI:
10.1183/09031936.02.01372002
.
[125]
Levine SJ , Kennedy D , Shelhamer JH ,et al.
Diagnosis of
Pneumocystis carinii
pneumonia by multiple lobe, site-directed bronchoalveolar lavage with immunofluorescent monoclonal antibody staining in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis
[J]. Am Rev Respir Dis， 1992，146(4)：838-843. DOI:
10.1164/ajrccm/146.4.838
.
[126]
Sun A , Gou X , Zhu Y ,et al.
Identification of
Talaromyces marneffei
infection in an HIV-negative patient by ITS sequencing
[J]. Infect Drug Resist， 2023，16：5275-5282. DOI:
10.2147/IDR.S418174
.
[127]
Costa JM , Botterel F , Cabaret O ,et al.
Association between circulating DNA, serum (1→3)-β-D-glucan, and pulmonary fungal burden in
Pneumocystis
pneumonia
[J]. Clin Infect Dis, 2012,55(2)：e5-8. DOI:
10.1093/cid/cis412
.
[128]
Huang YS , Liu CE , Lin SP ,et al.
Echinocandins as alternative treatment for HIV-infected patients with
Pneumocystis
pneumonia
[J]. AIDS, 2019，33(8)：1345-1351. DOI:
10.1097/QAD.0000000000002207
.
[129]
Ungprasert P , Permpalung N , Srivali N ,et al.
Pneumocystis
pneumonia during primary HIV infection: a case report and review of the literature
[J]. J Infect Chemother, 2013，19(5)：990-991. DOI:
10.1007/s10156-013-0568-y
.
[130]
Qi H , Dong D , Liu N ,et al. Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection[J]. BMC Infect Dis, 2023,23(1)：409. DOI:
10.1186/s12879-023-08372-z
.
[131]
Huang Y , He X , Chen H ,et al.
No statistically apparent difference in antifungal effectiveness observed among trimethoprim/sulfamethoxazole plus clindamycin or caspofungin, and trimethoprim/sulfamethoxazole monotherapy in HIV-infected patients with moderate to severe
Pneumocystis
pneumonia: results of an observational multicenter cohort study
[J]. Infect Dis Ther, 2022，11(1)：543-557. DOI:
10.1007/s40121-021-00586-5
.
[132]
[133]
Wickes BL , Wiederhold NP . Molecular diagnostics in medical mycology[J]. Nat Commun, 2018，9(1)：5135. DOI:
10.1038/s41467-018-07556-5
.
[134]
Samaddar A , Sharma A . Emergomycosis, an emerging systemic mycosis in immunocompromised patients: current trends and future prospects[J]. Front Med (Lausanne), 2021，8：670731. DOI:
10.3389/fmed.2021.670731
.
[135]
Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America[EB/OL]. [ 2024-10-10]. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection.
[136]
中华医学会检验分会临床微生物学学组. 成人耳念珠菌感染诊治防控专家共识[J]. 临床检验杂志， 2020,38(8):564-570. DOI：
10.13602/j.cnki.jcls.2020.08.02
.
[137]
Bupha-Intr O , Butters C , Reynolds G ,et al.
Consensus guidelines for the diagnosis and management of invasive fungal disease due to moulds other than
Aspergillus
in the haematology/oncology setting, 2021
[J]. Intern Med J, 2021,51：Suppl 7-177. 219DOI:
10.1111/imj.15592
.
[138]
Office of AIDS Research Advisory Council. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV[EB/OL]. [ 2024-09-16]. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/adult-adolescent-oi-2024-9-16.pdf.
[139]
Hoenigl M , Salmanton-García J , Walsh TJ ,et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology[J]. Lancet Infect Dis, 2021，21(8)：e246-e257. DOI:
10.1016/S1473-3099(20)30784-2
.
[140]
Yildirim I , Kao CM , Tippett A ,et al. A retrospective test-negative case-control study to evaluate influenza vaccine effectiveness in preventing hospitalizations in children[J]. Clin Infect Dis, 2021，73(10)：1759-1767. DOI:
10.1093/cid/ciab709
.
[141]
Thompson GR 3rd , Le T , Chindamporn A ,et al. Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology[J]. Lancet Infect Dis, 2021，21(12)：e364-e374. DOI:
10.1016/S1473-3099(21)00191-2
.
[142]
Mycetoma Rearch Center. Mycetoma management guidelines[EB/OL].[ 2024-06-21]. https://mycetoma.edu.sd/?page_id=3296.
[143]
Chapman SW , Dismukes WE , Proia LA ,et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008,46(12)：1801-1812. DOI:
10.1086/588300
.
[144]
Kauffman CA , Hajjeh R , Chapman SW . Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America[J]. Clin Infect Dis, 2000,30(4)：684-687. DOI:
10.1086/313751
.
备注信息
A
卢洪洲，国家感染性疾病临床医学研究中心 深圳市第三人民医院感染与免疫科，深圳 518112，Email:
nc.defudabe.hcetsus.yszsuohzgnohul；
B
李太生，中国医学科学院 北京协和医学院 北京协和医院感染内科，北京 100730，Email:
tendef.3ab62hstil；
C
沈银忠，上海市(复旦大学附属)公共卫生临床中心感染与免疫科，上海 201508，Email:
nc.defgrabo.chphsgnohzniynehs
D
所有作者声明无利益冲突
E
深圳市重大新发突发传染病临床医学研究中心项目 (深科创资202416号)
深圳市高水平医院建设院内配套经费（传染感染科） (XKJS-CRGRK-009)
广西重点研发计划 (桂科AB23026050)
深圳市"三名工程"医学团队项目 (SZSM202311033)
上海申康医院发展中心市级医院诊疗技术推广及优化管理项目 (SHDC22024317)
深圳市战略性新兴产业专项资金 (F-2022-Z99-502266)
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
中国自身免疫性脑炎诊治专家共识（2022年版）
中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组 中华神经科杂志 2022,55(09)
人类免疫缺陷病毒感染/艾滋病合并结核分枝杆菌感染诊治专家共识
中国性病艾滋病防治协会HIV合并结核病专业委员会 中华传染病杂志 2022,40(01)
艾滋病合并侵袭性真菌病诊治专家共识
中华医学会热带病与寄生虫学分会艾滋病学组 中华传染病杂志 2019,37(10)
艾滋病合并侵袭性真菌病诊治专家共识
中华医学会热带病与寄生虫学分会艾滋病学组 中华临床感染病杂志 2019,12(04)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
